Clinical Trials
41 trialsNCT04154956 2026-05-18
CARMEN-LC03
Sanofi
Phase 3 Terminated
NCT06038539 2026-03-13
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Biocon Limited
Phase 3 Terminated
NCT04921358 2025-06-29
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT05207514 2024-05-17
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT04171284 2024-02-09
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd.
Phase 3 Terminated
NCT02654587 2024-02-02
ATALANTE-1
OSE Immunotherapeutics
Phase 3 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT05106335 2023-08-16
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT00651326 2023-08-04
DART
Canadian Cancer Trials Group
Phase 3 Terminated
NCT00738387 2020-12-24
ATTRACT-2
Novartis
Phase 3 Terminated
NCT00054184 2020-10-05
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT00625898 2020-09-10
BETH
NSABP Foundation Inc
Phase 3 Terminated
NCT02076594 2019-10-09
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT02766140 2019-01-18
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT00863512 2017-03-27
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02144012 2017-03-07
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT00912444 2016-11-22
NATT
Shanghai Jiao Tong University School of Medicine
Phase 3 Terminated
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT01798485 2016-07-01
Galaxy 2
Synta Pharmaceuticals Corp.
Phase 3 Terminated
NCT00024167 2016-03-22
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00345059 2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT01282151 2015-07-14
TRAIL
Chonnam National University Hospital
Phase 3 Terminated
NCT00088907 2015-05-06
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00633568 2015-02-12
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
European Lung Cancer Working Party
Phase 3 Terminated
NCT00053911 2014-12-16
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
UNICANCER
Phase 3 Terminated
NCT00514917 2013-11-04
Rising PSA
Sanofi
Phase 3 Terminated
NCT00113399 2013-07-02
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
Radiation Therapy Oncology Group
Phase 3 Terminated
NCT00113386 2013-06-28
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 3 Terminated
NCT00268372 2012-10-04
S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx
SWOG Cancer Research Network
Phase 3 Terminated
NCT00442026 2012-06-27
Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC
Hellenic Oncology Research Group
Phase 3 Terminated
NCT00705822 2010-11-30
PROSTATA
Sanofi
Phase 3 Terminated
NCT00089856 2008-11-05
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Cell Genesys
Phase 3 Terminated
NCT00133224 2008-09-23
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Cell Genesys
Phase 3 Terminated
NCT00273338 2007-11-06
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
Novacea
Phase 3 Terminated
NCT00243204 2007-06-08
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Point Therapeutics
Phase 3 Terminated